Remove Avalon Remove Pricing Remove Startup
article thumbnail

Janux Therapeutics Prices IPO, Hits Nasdaq Today

socalTECH

La Jolla-based biopharmaceuticals startup Janux Therapeutics said early this morning that it has priced its IPO, offering up 11,400,000 shares of its common stock at $17.00 The company's biggest shareholders before the IPO were Avalon Ventures, RA Capital Healthcare, Orbimed, Bregua Corporation, and Correlation Ventures.

Pricing 113
article thumbnail

Interview with Derrick Oien, Intercasting

socalTECH

in funding from Venrock, Avalon, and Masthead. So do these show up as your brand or as an OEM deal with the carriers? Historically, it was something that started to develop before our launch with operators back in 2005, and it now serves as a laboratory for development of our product. Intercasting is backed by $17.5M a month.